Abstract

High affinity SIRP-α reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRPα reagent, which blocks the physiological binding interaction between SIRPα and its ligand CD47.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Systems and methods for predictive glucose in accordance with embodiments of the invention are illustrated. One embodiment includes glucose management device, including a brain signal recorder, and a controller, including a processor, and a memory, the memory containing a glucose monitoring application configured to direct the processor to record a brain activity signal of a user's brain using the brain signal recorder, and decode the brain activity signal to predict future glucose levels of the patient.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value

Abstract

In certain specific examples, methods and semiconductor structures are directed to a semiconductor device developed based on a two-step annealing process. In the first step, diffusion doping is used to apply (which may include, e.g., depositing a doped layer) a dopant towards a target region of a wafer or a transistor-device layer by effecting an early anneal while a thin layer of dopant-inclusive material is formed on, or spun onto, the target region. This may be implemented to provide a diffusion-doped dopant profile into the target region that is characterized in terms of flatness and depth. The second step involves providing a later anneal, while the target region is exposed to an ambient gas, to alter the dopant profile by increasing flatness and depth aspects of dopant profile.

IPC Classes  ?

• H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth
• H01L 21/203 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth using physical deposition, e.g. vacuum deposition, sputtering
• H01L 21/205 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth using reduction or decomposition of a gaseous compound yielding a solid condensate, i.e. chemical deposition
• H01L 21/225 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regionsRedistribution of impurity materials, e.g. without introduction or removal of further dopant using diffusion into, or out of, a solid from or into a solid phase, e.g. a doped oxide layer
• H01L 21/383 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regions using diffusion into, or out of, a solid from or into a gaseous phase
• H10D 62/17 - Semiconductor regions connected to electrodes not carrying current to be rectified, amplified or switched, e.g. channel regions
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• H01L 21/22 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regionsRedistribution of impurity materials, e.g. without introduction or removal of further dopant
• H01L 21/38 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regions
• H10D 62/10 - Shapes, relative sizes or dispositions of the regions of the semiconductor bodiesShapes of the semiconductor bodies
• H10D 62/13 - Semiconductor regions connected to electrodes carrying current to be rectified, amplified or switched, e.g. source or drain regions

Abstract

Methods for the early detection of subjects at risk of developing rheumatoid arthritis, and subjects having early rheumatoid arthritis thus allowing for early intervention.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The disclosure relates to pharmaceutical composition comprising dopamine antagonists and methods of using the same to treat pain, prevent drug liking and opioid addiction.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/33 - Heterocyclic compounds

Abstract

Disclosed is a method to achieve digital quantification of DNA (i.e., counting differences between identical sequences) using direct shotgun sequencing followed by mapping to the chromosome of origin and enumeration of fragments per chromosome. The preferred method uses massively parallel sequencing, which can produce tens of millions of short sequence tags in a single run and enabling a sampling that can be statistically evaluated. By counting the number of sequence tags mapped to a predefined window in each chromosome, the over- or under-representation of any chromosome in maternal plasma DNA contributed by an aneuploid fetus can be detected. This method does not require the differentiation of fetal versus maternal DNA. The median count of autosomal values is used as a normalization constant to account for differences in total number of sequence tags is used for comparison between samples and between chromosomes.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6869 - Methods for sequencing
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

Devices, systems, and methods for a wearable, real-time cognitive behavioral detection and/or therapy device for detecting impulsivity states of a user, and for providing alerts to the patient and/or a patient-identified network of persons, of an impending impulsivity state. The device utilizes a combination of wearable, non-invasive, sensors configured to be worn by a user and to detect electrophysiology signals and/or psychophysiological signals of the user. The sensors output respective sensor signals corresponding to the electrophysiology signals and psychophysiological signals and transmit the respective sensor signals to a computing device. The computing device has a software application which programs the computing device to process the sensor signals and provide informational and/or therapeutic information regarding an impulsivity state of the user. The device may also include a system for delivering electrical stimulation directly to the user in response to the impulsivity state detected by the device.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Provided are methods of differentiating ventral pharyngeal pouch endoderm (PPEv) cells to thymic epithelial progenitor cells (TEPCs). Such methods comprise culturing PPEv cells in a TEPC differentiation medium comprising an inflammasome activator, a nuclear factor-kappa B (NF-κB)/Toll-like receptor (TLR) signaling activator, a TLR signaling activator, a tumor necrosis factor (TNF) signaling activator, or any combination thereof. Also provided are methods of producing mature thymic epithelial progenitor cells (matTEPCs). Such methods comprise culturing TEPCs in a TEPC maturation medium comprising an inflammasome activator, a nuclear factor-kappa B (NF-κB)/Toll-like receptor (TLR) signaling activator, a TLR signaling activator, a tumor necrosis factor (TNF) signaling activator, or any combination thereof. TEPCs and matTEPCs produced according to the methods of the present disclosure are also provided, as are compositions comprising the TEPCs and matTEPCs. Methods of using the TEPCs and matTEPCs, e.g., for therapeutic purposes in athymic or hypothymic subjects, are also provided.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

Abstract

Water-soluble conjugates of verteporfin are provided, which find therapeutic use, including by topical administration. Also provided are liposomal verteporfin formulations, which may be admixed with biomolecules such as hyaluronic acid.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 9/51 - Nanocapsules
• A61P 27/02 - Ophthalmic agents

Abstract

The disclosure provides methods for preventing unintended concatemeric insertions arising from CRISPR/AAV-mediated genetic modifications to increase editing efficiency, decrease off-target effects, and improve on-target fidelity. Also provided are digital droplet PCR-based methods for evaluating complex genotypes and detecting unintended concatemeric insertions.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/864 - Parvoviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

Switchable and/or tunable surface topography is provided using a polymer having a crosslinking pattern formed within it. In operation the polymer is exposed to a liquid and it is switched or tuned between its various states by changing properties of the liquid. One of these states is a reference or " flat" state where the polymer thickness is substantially constant and the pattern is not apparent. In other states, the polymer swells in a pattern that corresponds ( inversely) to the crosslinking pattern. The less crosslinking there is at a point in the polymer, the more swelling there is at that point. The top and/or bottom surfaces of the polymer can be coated with metal to enhance the optical effects of these controllable thickness changes. By stacking such polymer layers, various combined functions are provided, such as independent control of texture and color.

IPC Classes  ?

• G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
• G02B 5/30 - Polarising elements
• G02B 6/35 - Optical coupling means having switching means
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• G02B 1/08 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of polarising materials
• G02B 6/10 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
• C08K 5/00 - Use of organic ingredients

Abstract

The invention provides a human cell-based delivery system for performing in vivo genetic modifications. The human cells are engineered to express and secrete one or more components of a gene editing technology which are taken up by target cells in vivo such that the target cells are genetically modified.

IPC Classes  ?

• C12N 7/02 - Recovery or purification
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
• A61K 38/46 - Hydrolases (3)
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases

Abstract

Systems and methods for enhancing yield of synthesis and molecular processing of nucleic acid species are described. Nucleic acid species can be synthesized or molecularly processed in batches or pools. The nucleic acid species within a batch or pool have been determined to have a similar yield efficiency with the other nucleic acid species within its batch or pool.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 40/20 - Supervised data analysis
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided are methods of treating pain in a subject in need thereof. The methods comprise administering to the subject a senolytic in an amount effective to treat the pain. According to some embodiments, the senolytic is administered as the only active agent to treat the pain. In other embodiments, the senolytic is administered in combination with a second active agent (e.g., a second senolytic or non-senolytic active agent) to treat the pain. Non-limiting examples of pain treatable by the methods include chronic inflammatory pain, surgery-induced pain, complex regional pain syndrome (CRPS) type 1 or type 2, neuropathic pain, diabetic peripheral neuropathy, and age-related pain. Also provided are kits that find use in practicing the methods of the present disclosure.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

A force sensor includes one or more upconverting nanoparticles. Each of the one or more upconverting nanoparticles include an emitter. The force sensor also includes a polymeric host at least partially around the one or more upconverting nanoparticles. The polymeric host exhibits electronic-vibrational coupling with the emitter in a stress dependent manner.

IPC Classes  ?

• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
• G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
• G01N 21/64 - FluorescencePhosphorescence
• G01L 5/18 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring ratios of force

Abstract

Electrospun nanofiber membranes are provided. The membranes are electrospun from a suitable biocompatible and biodegradable biopolymer, e.g. gelatin, collagen, etc., to generate a membrane, which is then cross-linked. The membrane may be seeded with cells. The compositions find use tissue regeneration, particularly in repair, regeneration, and/or reconstruction of lamellar or partial defects of wounded corneal tissue.

IPC Classes  ?

• D01D 5/00 - Formation of filaments, threads, or the like
• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61L 27/14 - Macromolecular materials

Abstract

In one aspect, the disclosure relates to a method for oxidizing alkanes to produce industrially useful solvents and other compounds. In a further aspect, the method includes the steps of contacting an alkane or mixture of alkanes with a core-shell nanoparticle and an oxidant to produce a mixture and then irradiating the mixture with UV and/or visible light. The methods are selective for desired products and do not produce overoxidized species such as, for example, carbon dioxide. In a still further aspect, the methods are scalable and can be conducted for a short time under relatively mild conditions. In an aspect, the core-shell nanoparticle includes a metal-oxide containing semiconductor core, an amorphous, radiation transparent shell, and optional metal nanoparticle dopants in the shell. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• C07C 51/275 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with oxides of nitrogen or nitrogen-containing mineral acids of hydrocarbyl groups
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 21/08 - Silica
• B01J 23/52 - Gold
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/39 - Photocatalytic properties
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/04 - Mixing
• B01J 37/06 - Washing
• B01J 37/08 - Heat treatment
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• C07C 29/48 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
• C07C 29/50 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups with molecular oxygen only
• C07C 45/28 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of —CHx-moieties
• C07C 45/34 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of CHx-moieties in unsaturated compounds
• C07C 51/25 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with molecular oxygen of unsaturated compounds containing no six-membered aromatic ring
• C07C 407/00 - Preparation of peroxy compounds

Abstract

Compositions and methods are provided to enrich for DNA corresponding to a genome of interest, e.g. by species, clade, or strain of origin, from a mixed population of nucleic acid sequences. The methods may further comprise identification of the genomic sequences of interest, e.g. identifying the species, clade, strain, etc. of origin.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• C12Q 1/6869 - Methods for sequencing

Abstract

Integrated systems and methods are provided for non-photosynthetic microbial conversion of low concentrations of dissolved inorganic carbon (DIC), including from alkaline solutions, to capture, concentrate, and store CO2 as methane (CH4) biogas or any other reduced organic compound. The methods allow CO2 capture and conversion, and can provide a source of hydrocarbons for synthesis, energy generation, carbon storage, and the like. The methods disclosed herein produce end products at high selectivity relative to chemical catalysis systems.

IPC Classes  ?

• C12P 5/02 - Preparation of hydrocarbons acyclic
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• C02F 101/10 - Inorganic compounds
• C02F 103/08 - Seawater, e.g. for desalination
• C12M 1/107 - Apparatus for enzymology or microbiology with means for collecting fermentation gases, e.g. methane
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

A pneumatic haptic sleeve is provided which is knit in one piece with a top side and a bottom side. The top side has a relatively soft and stiff stiffness areas. The soft areas are of increasing stiffness, where the softest is right beneath pneumatic actuators and allows for actuator deformation. The high stiff area is above and around the pneumatic actuators. The pneumatic actuators fit within the knitted sleeve such that the top side of the pneumatic actuator matches up with the high stiffness area, and the bottom side of the pneumatic actuator matches up with the low stiffness area. The pneumatic actuator has two states: actuated and non-actuated. The pneumatic haptic sleeve is portable, self-contained, and comfortable to wear, thereby promoting extended wearability and more consistent use in mediated social touch applications.

IPC Classes  ?

• G08B 6/00 - Tactile signalling systems, e.g. personal calling systems

Abstract

The present disclosure provides a barcode and print approach that links particular members of pooled sequenced libraries to specific protein variants that interact with the particular library members; and devices that allow such library-on library measurements.

IPC Classes  ?

• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6869 - Methods for sequencing
• C40B 60/14 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A chemical reactor for inductive heating has a non-conductive reactor wall (104) defining an interior (106) of the reactor, a conductive electromagnetic metamaterial susceptor (102) having an open cell 3D lattice structure distributed throughout a volumetric region within the interior of the reactor, electromagnetic coils (100) surrounding the susceptor, and a power supply (116) connected to the electromagnetic coils and adapted to produce AC electrical power at a predetermined operating frequency, thereby generating an electromagnetic field having a predetermined wavelength causing inductive heating of the susceptor. The susceptor has a predetermined effective AC conductivity response Gefr as a predetermined function of position within the volumetric region at the predetermined operating frequency.

IPC Classes  ?

• B01J 19/32 - Packing elements in the form of grids or built-up elements for forming a unit or module inside the apparatus for mass or heat transfer
• B01J 6/00 - CalciningFusing

Abstract

A sensor system includes a ranged sensor that generates time-series data indicating positions of objects in an environment, and at least one processor that receives the time-series data generated by the ranged sensor, encodes the time-series data into edge embeddings with an encoder, and computes edge features and edge logits of the objects in the environment, represented in a latent space, based on the edge embeddings. The at least one processor also disentangles the edge features in the latent space, and generates a representation of time-invariant latent characteristics of interactions between the edge features in the latent space.

IPC Classes  ?

• G01S 7/48 - Details of systems according to groups , , of systems according to group
• G01S 17/06 - Systems determining position data of a target
• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging

Abstract

Provided are methods of generating cells that produce monoclonal antibodies that specifically bind domain 2 of a human lymphocyte activation gene-3 (LAG-3) polypeptide. The methods comprise immunizing a non-human animal with an immunogen comprising domain 2 of a human LAG-3 polypeptide and isolating monoclonal antibody-producing cells from the non-human animal, wherein the monoclonal antibody-producing cells produce monoclonal antibodies that specifically bind the immunogen. Such methods further comprise screening the monoclonal antibody-producing cells for cells that produce monoclonal antibodies that specifically bind domain 2 of human LAG-3. Also provided are in vitro methods of identifying a polypeptide that specifically binds domain 2 of a human LAG-3 polypeptide, as well as in silico methods of identifying an agent as a candidate human LAG-3 dimerization disrupting agent. Antibodies, polypeptides and agents identified according to the methods of the present disclosure are also provided.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods of promoting healing of a wound in a dermal location of a subject are provided. Aspects of the methods may include administering an effective amount of a Piezo inhibitor composition to the wound to promote healing of the wound, e.g., by reducing transition of adipocytes to fibroblasts in the wound. Also provided are methods of preventing or reversing scarring during healing of a wound in a subject. Aspects of the methods may include forming a wound in a dermal location of a subject and administering an effective amount of a Piezo inhibitor composition to the wound to promote regenerative healing or regenerative remodeling of the wound. Also provided are methods of ameliorating, e.g., reducing or inhibiting, organ fibrosis, e.g., liver fibrosis, heart fibrosis, inflammatory bowel fibrosis, muscle fibrosis, kidney fibrosis, etc., in a subject by administering to the subject an effective amount of a Piezo inhibitor composition. Also provided are kits including an amount of a Piezo inhibitor composition.

IPC Classes  ?

• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present disclosure generally relates to, inter alia, recombinant immune cells that have been engineered to express reduced levels of one or more subunits of the mediator complex, and particularly relate to engineered immune cells exhibiting enhanced effector functions. Also provided are methods for generating engineered immune cells with enhanced effector function, pharmaceutical compositions the same, as well as methods and kits for the prevention and/or treatment of a health condition in subjects in need thereof.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Sensors described in this disclosure have unexpectedly improved stability in challenging environments, including whole blood. The increased stability is at least partly result of a polymer coating that covers a nanoporous layer. The polymer coating allows analytes to travel through to recognition elements within a nanopore in the nanoporous layer. The polymer coating and the nanopore reduce or eliminate the travel of interferents to degrade or foul the recognition elements. The nanoporous layer may define a nanopore or plurality of nanopores. The recognition element may be in contact with the nanoporous layer and disposed in the nanopore. The recognition element may be configured to bind to the analyte to form a complex that sends a signal. Systems, methods of making the systems, and methods of using the systems are described.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6825 - Nucleic acid detection involving sensors
• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

Disclosed herein are compounds that can degrade proteins having an active role in cancer progression, including CK1α (a negative regulator of the canonical Wnt pathway) and WEE1 (a G2/M checkpoint kinase). Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of proliferative diseases such as cancers.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/33 - Heterocyclic compounds

Abstract

Provided herein are compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression. In particular, synthetic transcription factors comprising one or more transcriptional activator domains, one or more transcriptional repressor domains, or a combination thereof fused to a heterologous DNA binding domain, and methods of using thereof are provided.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Malaria still afflicts about half of the world population causing more than 400,000 deaths, mostly children. The options for malaria therapy are increasingly becoming limited because of widespread drug resistance. Furthermore, drugs for prophylaxis are suboptimal. This disclosure reports the identification of type II protein kinase inhibitor compounds which have never been explored as antimalarial agents and which now have been discovered to possess therapeutic and prophylactic properties against malaria.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 33/06 - Antimalarials
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Methods and systems for detecting cell states in a biological sample are disclosed. Methods and systems for predicting a therapeutic response, a severe immune-related adverse event (irAE), a symptomatic irAE, and an irAE grade of a subject to be administered an immunotherapy treatment based on cell states detected from a single biological sample from the subject are also disclosed.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Systems and methods of verifying a hardware processing circuit design for a digital system are disclosed. Three different computer models of the same hardware are implemented. The first computer model is implemented on a first sequence of action inputs and a second sequence of action inputs. The second computer model is implemented on the first sequence of action inputs and is allowed to idle until the first sequence is done. The architectural states of the second computer model are then recorded. The third computer model is implemented on the second sequence after having set the third computer model to the recorded architectural states. The outputs of the first computer model and the third computer model are implemented to check for functional consistency. The techniques described herein can be used to check digital designs for functional consistency, are sound and complete, and do not require an understanding of implementation details.

IPC Classes  ?

• G06F 30/33 - Design verification, e.g. functional simulation or model checking
• G06F 115/02 - System on chip [SoC] design

Abstract

Engineered synthetic signaling molecules, herein termed "trikines", are provided. Trikines are genetically engineered, tri-specific ligands of cell surface receptors, where the trikine specifically binds at high affinity to the extracellular domains of three different cell surface receptor polypeptides. In some embodiments, generation of a receptor multimer by binding to a trikine results in intracellular trans-phosphorylation of receptor subunits. In some embodiments trikines modulate STAT signaling that results from the receptor binding and mutimerization.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 19/00 - Hybrid peptides

Abstract

The invention provides compositions and methods for the ex vivo expansion and maintenance of mammalian hematopoietic stem and progenitor cells (HSPCs), including human HSPCs.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C07K 14/52 - CytokinesLymphokinesInterferons

Abstract

An example system for passive sensing includes a coupled pair of resonators including a sensor resonator and a reader resonator, the sensor resonator including a resistor a loss associated with the resistor, and the reader resonator including a MOS cross-coupled pair that implements a nonlinear gain of the reader resonator via compressive saturation of negative resistance. An amplitude detector measures the amplitude of oscillations associated with the reader resonator, and the negative resistance is determined based on the measured amplitude of oscillations associated with the reader resonator when the measured amplitude reaches a steady state, i.e., when the gain of the reader resonator balances the loss of the sensor resonator. The resistance associated with the resistor of the sensor resonator may be determined based on the determined negative resistance. When the resistor is a resistive sensor, indications of measurements by the resistive sensor may be determined in this way.

IPC Classes  ?

• H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom

Abstract

Small molecules compounds and methods of their synthesis are provided. Small molecules identified can inhibit histone acetyltransferase 1 activity. Formulations and medicaments are also provided that are directed to the treatment of human disorders and conditions, such as, for example, neoplasms, cancers, viral, fungal, and parasitic infections, and aging. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

IPC Classes  ?

• C07D 475/14 - Benz [g] pteridines, e.g. riboflavin
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2

Abstract

Aspects of the present disclosure include polymeric structures having one or more polymeric microneedles. Polymeric structures according to certain embodiments exhibit a macrostructural change (e.g., exhibit elastic deformation) in response to an applied stimulus. In some embodiments. polymeric structures include a microarray of polymeric microneedles for delivering an active agent compound to a subject or for collecting a biological fluid sample from a subject. Methods for applying a polymeric structure having polymeric microneedles to a skin surface of a subject is also described. Methods for making the polymeric structures, such as by high resolution continuous liquid interface production is also provided. Kits having one or more of the subject polymeric structures are also described.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Systems and methods for clinical neuronavigation in accordance with embodiments of the invention are illustrated. One embodiment includes a method for generating a brain stimulation target, including obtaining functional magnetic resonance imaging (fMRI) image data of a patient's brain, where brain imaging data describes neuronal activations within the patient's brain, determining a brain stimulation target by mapping at least one region of interest to the patient's brain, locating functional subregions within the at least one region of interest based on the fMRI image data, determining functional relationships between at least two brain regions of interest, generating parameters for each functional subregion, generating a target quality score for each functional subregion based on the parameters and selecting a brain stimulation target based on its target quality score and the patient's neurological condition.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• G01R 33/48 - NMR imaging systems
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Compositions and methods are provided for determining minimal residual disease (MRD) in cancer patients following therapy. In some embodiments the patient is a breast cancer patient that has been treated with NAC. The methods, termed spatial MRS (s-MRD) apply blood-based assessment tools to tumor tissue to accurately characterize molecular residual disease.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6851 - Quantitative amplification
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignmentHomology search

Abstract

Systems and methods for state-of-charge estimation in accordance with embodiments of the invention are illustrated. One embodiment includes a battery management system, including a pulse generator configured to provide constant current pulses to a battery, a voltage sensor configured to measure output voltage of the battery, and a state-of-charge monitor, including a processor, and a memory storing a state-of-charge monitoring application that configures the processor to apply a constant current pulse to the battery using the pulse generator, measure the output voltage of the battery in response to constant current pulse, calculate a pulse inverse derivative of a galvanostatic voltage response of the battery, pulse dQ/dV, based on the measured output voltage, estimate a state-of-charge of the battery using the estimated pulse dQ/dV and a complete dQ/dV curve of the battery across a range of state-of-charge of the battery, and provide the estimated state-of-charge.

IPC Classes  ?

• G01R 31/382 - Arrangements for monitoring battery or accumulator variables, e.g. SoC
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/374 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC] with means for correcting the measurement for temperature or ageing

Abstract

Systems and methods for state-of-charge monitoring in accordance with embodiments of the invention are illustrated. One embodiment includes a battery management system including a sine-wave pulse generator configured to provide sine-wave pulses to a battery, a voltage sensor configured to measure output voltage of the battery, and a state-of-charge monitor, including a processor, and a memory storing a state-of-charge monitoring application that configures the processor to apply a sine-wave pulse current to the battery using the sine-wave pulse generator, measure the output voltage of the battery in response to the sine wave pulse current, estimate an impedance of the battery based on the voltage response, estimate a state-of-charge of the battery using the estimated impedance of the battery, and provide the estimated state-of-charge.

IPC Classes  ?

• G01R 31/382 - Arrangements for monitoring battery or accumulator variables, e.g. SoC
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/374 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC] with means for correcting the measurement for temperature or ageing

Abstract

In certain examples, methods and semiconductor structures are directed to devices and methods involving a semiconductor device with a current-blocking layer (CBL) and a first material layer having n-type dopant material that is activated with recovered crystallinity. The CBL may have a surface portion along a plane of the CBL (e.g., in a transistor, the CBL may be between the first material layer and another material layer). A p-type dopant material is located or diffused into the CBL and activated without recovered crystallinity, and the CBL's dopant profile is characterized as corresponding to an outer portion of the CBL with a higher concentration of the p-type dopant material than a concentration of the p-type dopant material in an inner portion of the CBL.

IPC Classes  ?

• H10D 62/80 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials
• H01L 21/385 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regions using diffusion into, or out of, a solid from or into a solid phase, e.g. a doped oxide layer
• H10D 30/01 - Manufacture or treatment
• H10D 30/66 - Vertical DMOS [VDMOS] FETs
• H10D 62/17 - Semiconductor regions connected to electrodes not carrying current to be rectified, amplified or switched, e.g. channel regions

Abstract

Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

IPC Classes  ?

• A61K 31/12 - Ketones
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/433 - Thiadiazoles
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 487/04 - Ortho-condensed systems
• G01N 21/64 - FluorescencePhosphorescence

Abstract

Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

In one embodiment, a micro-cooler assembly includes a manifold having at least one inlet for receiving a liquid, a plurality of fins, wherein each fin of the plurality of fins includes a micro-channel, and a plurality of vapor gaps interlaced with the plurality of fins. A width of the micro-channels is graded, and/or a width of the vapor gaps is graded. The micro-cooler assembly further includes a cold plate that includes a surface and a wick region disposed on the surface. The manifold is coupled to the surface of the cold plate. The at least one inlet is operable to provide the liquid proximate the wick region. The liquid is operable to be wicked into the wick region through the micro-channels of the plurality of fins, and heating of the liquid changes phase to a vapor that exits the manifold through the plurality of vapor gaps.

IPC Classes  ?

• F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
• F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
• F28F 3/02 - Elements or assemblies thereof with means for increasing heat-transfer area, e.g. with fins, with recesses, with corrugations
• F28F 3/12 - Elements constructed in the shape of a hollow panel, e.g. with channels

Abstract

in situin situ in permeabilized nuclei, and then tethering chromatin-cleaving or -modifying enzymes. These methods are however limited by their requirement for a nuclear envelope to hold the chromatin together during wash steps and buffer exchanges. This results in large input material requirements due to sample losses, limitations in what types of samples can be processed, increased variability due to handling steps, and an inability to study chromatin outside of its compacted form in the nucleus. A new method for preparing chromatin from cells for downstream genomic chromatin mapping is disclosed. The method uses dilution, precipitation, and dialysis to replace wash steps and buffer exchanges, allowing the entire protocol to take place in a single tube with no removal of material prior to DNA extraction.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/6841 - In situ hybridisation
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Cells engineered with custom-designed receptors can efficiently transfer membrane-associated macromolecules into recipient cells upon contact, which can be freed from endosomes in recipient cells and optionally functionalized in a trogocytosis-like manner via pH-responsive membrane fusion. A variety of configurations, payload proteins and donor and recipient cells are possible with the methods descried herein.

Abstract

Devices and methods are provided for closing an incision through fascia or other tissue of a subject. A first closure element is positioned against tissue on a first side of the incision, a second closure element is positioned against tissue on a second side of the incision, and a fastener from or through the first closure element is directed through the tissue and the second closure element to secure the closure elements against the tissue to close the incision.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Optical spectroscopy based on adsorption of a sample on a surface of a mechanical resonator is provided. The sample is illuminated with light that is intensity modulated at or near the resonance frequency of a mode of the mechanical resonator. Thermal expansion caused by optical absorption at the sample effectively generates a force on the mechanical resonator that excites the resonant mode of the resonator. Thus a measurement of displacement or the like of the mechanical resonator (e.g., via the piezoelectric effect) provides the desired spectroscopic signal. Spectra can be obtained by sweeping a wavelength of the optical source or by using an optical dual-comb source having multiple emission wavelengths each intensity modulated at a different frequency.

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry

Abstract

Provided herein is a combination comprising: an optically transparent substrate, a sample that comprises biological analytes, and a layer of a conductive organic polymer. In this combination, the layer of polymer may be between the sample and the substrate, the layer of polymer may coat the section on the opposite side to the substrate, or both. The method comprises a liquid composition, wherein the composition comprises PEDOT, PSS, DMS02 and an organic solvent or polyaniline (emeraldine salt), DMS02 and an organic solvent; and wherein the applying comprises spraying, spin coating or spreading a composition comprising a solvent and the polymer on the surface of the substrate and then removing the solvent by evaporation. Methods of analyzing the sample in this combination are also provided.

IPC Classes  ?

• C09D 165/00 - Coating compositions based on macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCoating compositions based on derivatives of such polymers
• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• C08G 73/02 - Polyamines
• C09D 179/02 - Polyamines
• G01N 1/30 - StainingImpregnating
• H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances

Abstract

Methods are disclosed for predicting a likelihood of developing a severe immune-related adverse event (irAE) associated with the administration of an immunotherapy in a melanoma patient based on abundances of activated CD4 memory T cells and/or diversities of T cell receptors (TCR) within a peripheral blood sample obtained from the patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Aspects of the present disclosure include methods for making a polymeric structure having one or more microchannels. Methods according to certain embodiments include conveying a polymerizable composition through a conduit into a space between a build elevator and a build surface of a liquid interface production module, irradiating the polymerizable composition positioned between the build elevator and the build surface to generate a polymerizable composition having a first polymerized region of the polymerizable composition having a microchannel in contact with the build elevator and a first non-polymerized region of the polymerizable composition in contact with the build surface, displacing the build elevator away from the build surface, irradiating the first non-polymerized region of the polymerizable composition to generate a second polymerized region of the polymerizable composition in contact with the first polymerized region and a second non-polymerized region in contact with the build surface and repeating one or more steps in a manner sufficient to generate a polymeric structure having one or more microchannels positioned within the polymeric structure. Systems having a conduit for conveying a polymerizable composition to a liquid interface polymerization module having a build elevator and a build surface configured are also described. Polymer structures having a predetermined fluidic microchannel network prepared by the subject methods and non-transitory computer readable storage medium for practicing the subject methods are also provided.

IPC Classes  ?

• B29C 64/336 - Feeding of two or more materials
• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B29C 64/205 - Means for applying layers
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

There are provided herein, inter alia, complexes, compositions and methods for the delivery of nucleic acid into a cell in vivo. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

Devices are provided for performing endovascular surgical procedures. In one example, the device includes a magnetically actuated untethered rotation device, i.e., a magnetic spinner, that can navigate in blood vessels through its spinning-enabled propulsion. The magnetic spinner is capable of providing suction, shear force, carrying load for functions including navigation in multi-branched blood vessels, e.g., for targeted drug delivery, treating brain aneurysm, mechanical thrombectomy, rotablation for plaque removal, and the like.

IPC Classes  ?

• A61B 17/3207 - Atherectomy devices
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Systems and methods for expression and delivery of proteinaceous species are described. Generally, a system can comprise biological cells within a porous membrane. The biological cells can be utilized to produce proteinaceous species. The biological cells can further store proteinaceous species within secretory granules such that the species can be controllably released upon depolarization of the cell. A secondary force can be provided to release proteinaceous species out of the porous membrane. Proteinaceous species can be expressed from an expression cassette configured to provide controllable release.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61K 9/50 - Microcapsules
• A61K 35/39 - PancreasIslets of Langerhans
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

In one example, a semiconductor has a set of one or more scaffolding tiers, each tier of the set of one or more scaffolding tiers including a stack of material layers. The stacked layers include: a device layer in which at least one hot-spot region is located; a thin poly crystalline diamond (PCD) layer, located between the device layer and a thick layer, thermally coupled to said at least one hot-spot region of the device layer; and the thick layer has a plurality of diamond vias, providing respective thermal pathways, with diamond-via end portions that are thermally coupled to the PCD layer. The thick layer includes elongated diamond-filled thermal-pathway vias having end portions thermally coupled to the PCD layer for enabling thermal energy to flow from said at least one hot-spot region into and/or through the thick layer.

IPC Classes  ?

• H01L 23/373 - Cooling facilitated by selection of materials for the device
• H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• H01L 23/48 - Arrangements for conducting electric current to or from the solid state body in operation, e.g. leads or terminal arrangements

Abstract

Compositions comprising a therapeutic agent that induces a long QT interval and a cardioprotective agent are provided. Use of the compositions in managing risk of or actual QT prolongation are described, where the cardioprotective agent is administered before, during and/or after the therapeutic agent that induces a long QT interval.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61P 9/06 - Antiarrhythmics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

The present invention provides a clinically applicable method of hematopoietic stem cell transplantation using antibody-based immunosuppression, which can enable engraftment of hematopoietic stem cells. In particular, in Fanconi Anemia this treatment alone is sufficient to enable engraftment of allogeneic hematopoietic stem cells, even in mismatched settings. The methods are optionally combined with CD117 mAb conditioning.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)

Abstract

Compositions, methods, and kits are provided for treating bacterial infections with nanoclusters comprising a metallic core conjugated to a nucleotide. Recalcitrant infections are often difficult to treat because of the presence of persister cells, a subpopulation of bacterial cells that is highly tolerant of traditional antibiotics. Persister cells are dormant, which makes them less susceptible to many antibiotics, which are designed to kill growing cells. Administration of nanoclusters comprising a nucleotide was found to be highly efficacious in eradicating persister cells and for treating infections for a broad range of bacterial species, including Gram-positive and Gram-negative bacteria. Such treatment was effective not only in eradicating planktonic bacteria but also bacteria in biofilms.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 33/242 - GoldCompounds thereof
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 31/04 - Antibacterial agents

Abstract

Differential methylation profiles of a panel of genes are identified from colorectal carcinoma tissues of colorectal cancer patients compared to normal colon mucosal tissue or to white blood cells from healthy subjects. A high methylation level of cytosines at CpG dinucleotide sites (in CpG-rich regions) of the panel of genetic loci are further validated in plasma cell-free DNA as signature markers indicative of colorectal cancer, which is useful for early stage detection of colorectal cancer and monitoring of disease progression. This panel of genetic loci include genes MAP3K14-AS1, DNM1P46, EMBP1, GATM, VSV2, LAYN, and SFMBT2, which individually or in combination can complement SEPT9-based assays in improving sensitivity and/or specificity in the detection of colorectal cancer. Assay methods and reagents for detection of the presence and levels of methylation of the marker genetic loci are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing

Abstract

This disclosure provides recombinant DNA mol-encoding fusion proteins that are able to regulate expression of alpha-synuclein. Also provided are various compositions comprising the recombinant DNA molecules, as well as associated methods of use. The recombinant DNA molecules and associated methods are useful for the treatment of subjects having disorders caused by excess expression or intracellular accumulation of alpha-synuclein, including Parkinson's disease.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/16 - Anti-Parkinson drugs
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/86 - Viral vectors

Abstract

Methods and compositions are provided for the treatment of glaucoma and other optic neuropathies by administering an effective dose of an HDAC4 coding sequence or protein.

IPC Classes  ?

• C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/06 - Antiglaucoma agents or miotics
• C12N 15/86 - Viral vectors

Abstract

Compositions and methods are provided relating to a class of electrophilic aromatic reagents that react in high yields with RNA, resulting in heteroaryl or aryl adducts at 2¢-OH position of RNA. Multiple structural variants of reagents are described, along with applications in labeling, mapping, and profiling interactions of RNA. The reagents and reactive groups are easily synthesized, easily conjugated, function in pure water without organic solvents, are chemically stable for storage, and survive for extended times in water during reaction with RNA.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/33 - Heterocyclic compounds

Abstract

Provided are compounds that covalently bind to Fis1. Also provided are methods of selectively inhibiting mitochondrial dysfunction. Aspects of the methods include covalently binding a compound to Fis1. Also provided are methods for treating mitochondrial dysfunction in a subject by administering an effective amount of a compound that covalently binds to Fis1. Aspects of the methods include treating a subject that has a neurodegenerative disease, an inflammatory disease or a cardiovascular disease.

IPC Classes  ?

• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The disclosure relates to a system, composition and computer program products for determining the length of a telomere in a sample. Methods of diagnosing a subject with a telomeric disorder are also disclosed herein with steps of correlating the telomere length with the diagnosis of disease and, optionally, in connection with the detection of other information such as the presence of mutations at certain genes with the chromosomal DNA of the subject or the methylation frequency of the chromosomal DNA.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G16B 30/10 - Sequence alignmentHomology search
• C12Q 1/6869 - Methods for sequencing

Abstract

Chimeric antigen receptor T cells with a lectin binding domain are targeted to carbohydrate tumor antigens, particularly T antigen.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/42 - Lectins, e.g. concanavalin, phytohaemagglutinin
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 35/00 - Antineoplastic agents
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided herein is a method for detecting a target nucleic acid in a sample. In some embodiments, the method may comprise: (a) amplifying the target nucleic acid isothermally in the presence of one or more compaction oligonucleotides to produce a product that comprises condensed amplification products; (b) flowing the product through a microfluidic channel; and (c) detecting a change in impedance as the condensed amplification products pass through the microfluidic channel. A microfluidic system and kit for preforming the method are also provided.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Described herein is a method for identifying combinations of perturbations that result in a cellular phenotype. In some embodiments, the method may comprise making a library of cells that have received combinations of perturbations, analyzing a subset of the cells at a single cell level, by measuring a phenotype in the cells and identifying which combinations of perturbations have been applied to the cells and, based on the results obtained from the analysis, calculating scores for the identified combinations of perturbations and scores for theoretical combinations of the perturbations, wherein each score indicates the likelihood that a combination of perturbation generates the phenotype.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

De novo designed polypeptides that bind to IL-2 receptor βc heterodimer (IL-2Rβc), IL-4 receptor αc heterodimer (IL-4Rαc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• C07K 14/54 - Interleukins [IL]

Abstract

Adjustable mitral annuloplasty rings are disclosed that include a body including an anterior segment with a hub and first and second curved lateral segments extending from opposite ends of the anterior segment. In one example, the body terminates at tips of the lateral segments generally opposite the anterior segment to define a “C” shape. Alternatively, the body includes a posterior segment extending between ends of the lateral segments opposite the anterior segment to define a “D” shape. One or more channels are provided around a perimeter of the body, e.g., through the segments and communicating with openings in the hub, and a filament is received in the channels such that the filament extends around the perimeter of the body and ends of the filament exit the openings in the hub such that the ends may be tensioned to cause constriction of one or more of the segments of the body.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

Annuloplasty devices are provided for implantation around a tricuspid valve to avoid placement over a septal leaflet of the valve and/or avoid suture placement adjacent the septal leaflet. In one example, the device includes a “C” shaped body that includes spaced apart ends to provide a gap to avoid placement over the septal leaflet. Alternatively, a flexible portion may be connected to the ends of the “C” shaped body for placement over the septal region. In another example, the device includes an enclosed band including a contoured bridge configured to sit over the septal leaflet, e.g., to avoid unnecessary leaflet abrasion and/or conform to the septal wall and aorta.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

The present disclosure describes systems and methods for non-verbal communication. Aphasia and other speech related disorders can prevent people from communicating effectively or efficiently. Without effective communication, individuals can become depressed, anxious, and/or have worsening health outcomes. Many embodiments described herein allow for communication based on eye tracking of the individual to allow more effective and efficient communication between the individual and a third party, such as a family member or caretaker. Further embodiments are capable of monitoring mental state (e.g., depression and anxiety) and/or providing early detection of health events (e.g., stroke and cognitive decline).

IPC Classes  ?

• G09B 21/00 - Teaching, or communicating with, the blind, deaf or mute
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06F 3/0482 - Interaction with lists of selectable items, e.g. menus

Abstract

Systems and methods for confining an optical signal in a non-linear optical quantum computing system are disclosed. An optical signal and a trap field are provided in the non-linear optical quantum computing system. The trap field propagates with and confines the optical signal in time and/or space. The non-linear optical quantum computing system may be structured as a ring, a single-pass waveguide or a segmented single-pass waveguide. In some cases, multiple optical signals may be input into the system and evaluated in a multiplexed fashion.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G02F 1/365 - Non-linear optics in an optical waveguide structure

Abstract

The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

Systems and methods for randomized coordinated reset deep brain stimulation in accordance with embodiments of the invention are illustrated. One embodiment includes a deep brain stimulation system and a neurostimulator coupled to a plurality of electrodes, where the neurostimulator is configured to deliver randomized coordinated reset stimulation to a brain via the plurality of electrodes, where the coordinated reset stimulation comprises a plurality of consecutive time windows, where within each consecutive time window, a pulse is delivered by each electrode in the plurality of electrodes at a respective amplitude at a respective time in the time window, and wherein at least one of: the respective amplitude of the pulse for a given electrode in the plurality of electrodes is randomly varied in each consecutive time window, and the respective time of the pulse for a given electrode in the plurality of electrodes is randomly varied in each consecutive time window.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

Polypeptide constructs comprising a first peptide attached to a cell penetrating peptide, wherein the first peptide has both homology to a portion of the SNARE protein SNAP-25 and non-natural amino acids comprising one or two macrocyclic crosslinks, are provided herein. These polypeptide constructs are useful for disrupting the primary interface between SNAP-25 or its homolog and Syt1 or its homolog. Methods for treating a subject with mucus hypersecretion-based airway obstruction and/or developed mucus occlusions are also described, as well as methods of inhibiting mucin secretion in an airway epithelial cell.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 11/12 - Mucolytics
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure relates to methods of analyzing nucleic acids in a sample. In particular, provided herein are methods of analyzing a sample involving enriching for nucleic acids containing CpG sites in a sample and assessing methylation status in enriched nucleic acids.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 9/22 - Ribonucleases
• C12Q 1/6855 - Ligating adaptors
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]

Abstract

Disclosed herein are compounds that can be used to prepare prodrugs, methods of producing prodrugs using the compounds, and prodrugs produced by such methods. The prodrugs produced using the compounds disclosed herein are highly soluble, allowing for good oral bioavailability.

IPC Classes  ?

• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/015 - Hydrocarbons carbocyclic

Abstract

Systems and methods for assessment of circadian rhythm and sleep homeostasis are described. Presence of proteinaceous biomarkers within an individual's biological sample can be utilized in a computational classifier to indicate rhythmic phase and/or sleep homeostasis. Further clinical analysis and/or treatments can be performed based on determined rhythmic phase or sleep homeostasis.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow

Abstract

A process for converting carbon dioxide into a carbon-based molecule catalyzes a direct-conversion reaction of a vapor-fed flow of the carbon dioxide to the carbon-based molecule using a tandem electrocatalyst integrated with the gas diffusion electrode. The tandem electrocatalyst is a nanostructure composed of two parts: a copper or a copper-based binary or ternary alloy, and a metal center coordinated to nitrogen-doped carbon (NC) or a NC— containing macrocyclic organic compound. In one specific implementation, the tandem electrocatalyst consists of copper and nickel-coordinated nitrogen-doped carbon (NiNC), and the carbon-based molecule is ethylene. The copper or copper-based binary or ternary alloy may be in the form of nanoparticles, nanocubes, nanotubes, nanoflowers, nanorods, or nanoplates. The metal center coordinated to nitrogen-doped carbon (NC) or to a NC— containing macrocyclic organic compound may be in the form of nanoflowers, nanotubes, nanocages, mesopores, macropores, nanofibers, nanospheres, or other nanostructure.

IPC Classes  ?

• B01J 31/22 - Organic complexes
• B01J 35/45 - Nanoparticles
• C25B 3/01 - Products

Abstract

Certain examples are directed to an apparatus designed for use with an array of sensors to collect user signals indicative of kinematics and/or electrophysiology, corresponding to an observed region of the user. The apparatus (which may be characterized as a computer-implemented method) include a computer processing circuitry to use the signals as collected by the array of sensors by carrying out certain computer-programmed aspects or steps such as: training an algorithm to identify a pattern of physiological signals manifested by the use; generating, via the algorithm, data knowledge about relationships between the observed region and at least one unobserved region of the user that does not include the observed region; and extrapolating, in response to the generated data knowledge about relationships, further physiological signals of the user, corresponding to the unobserved regions.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• G06N 20/00 - Machine learning

Abstract

Coherent wavelength division multiplexing is provided using frequency comb sources for both the transmitter and the local oscillator (LO) in the receiver. The local oscillator is made phase coherent with the received multifrequency optical signal using two analog control loops. One of the control loops locks an optical frequency of the local oscillator to an optical frequency of the received frequency comb. The other control loop locks a microwave frequency of the local oscillator (i. e. LO the comb spacing) to the comb spacing of the received frequency comb. As a result, coherent detection is enabled in all channels with just two analog control loops. Control signals for the two loops can be derived from two of the received channels individually (asymmetric carrier recovery), or they can be derived from sum and difference signals from two of the received channels (symmetric carrier recovery).

IPC Classes  ?

• H04B 10/61 - Coherent receivers
• H04B 10/63 - Homodyne

Abstract

Described herein are methods of making and using and apparatus for wirelessly communicating data and providing power, particularly from a location exterior to a body and to an implantable device disposed within a body with tissue. The described embodiments provide apparatus and methods for efficiently transfer data and power between an external transceiver and an (implanted) biomedical device. The method is to modulate power carrier, which wirelessly powers the device, using an asynchronous modulation scheme, such as amplitude shift keying (ASK) modulation, with minimal modulation depth in order to not disrupt the power flow. The digital data is encoded in the pulse width, eliminating the need for synchronization to the power carrier signal and further minimizing the power consumption necessary for data transfer. Additionally, a reverse backscatter method for obtaining data from the implant is described that has flexible, low power operation.

IPC Classes  ?

• H04B 5/72 - Near-field transmission systems, e.g. inductive or capacitive transmission systems specially adapted for specific purposes for local intradevice communication
• H04B 5/79 - Near-field transmission systems, e.g. inductive or capacitive transmission systems specially adapted for specific purposes for data transfer in combination with power transfer

Abstract

Compositions and methods are provided relating to in vitro differentiation of vascularized two-and three-dimensional biological structures, which may be referred to herein as vascularized organoids (VOs). Vascularization in the organoids is spatially organized, and can include hierarchical branching of large vessels to small vessels. Features of the vascularized organoids include vascular tissues having the same branching structure and self-organization as seen in vivo; and physiologically relevant spatial organization within endocardial, myocardial, epicardial, and/or progenitor cells. The organoids also have inherent vascular beds that can be anastomosed immediately with host vasculature beds, thereby improving transplantation efficiency by rapid oxygenation from blood flowing through their pre-incorporated vascular beds.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Methods are provided for the treatment and prevention of fibrosis by administering an effective dose of a shear-thinning hydrogel formulation comprising a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex. In some embodiments the small molecule inhibitor of AP-1 is T-5224 (3-[5-(4-Cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy]phenyl]propanoic acid) or a derivative thereof, including prodrugs, salts, analogs, and the like. The inhibitor is applied locally, e.g. at the site of surgery that can predispose to adhesion formation.

IPC Classes  ?

• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/42 - Oxazoles
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances

Abstract

Systems and methods for three-dimensional fabrication of nanoscale products via triplet-triplet annihilation photon upconversion are provided. Generally, an optical system can be utilized to impinge patterned light onto a resin. The resin can comprise components triplet-triplet annihilation photon upconversion and components for polymerization. The patterned light provided by the optical system can induce triplet-triplet annihilation photon upconversion to stimulate polymerization and thus curing the resin.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09J 11/04 - Non-macromolecular additives inorganic

Abstract

e.g.e.g.e.g.e.g.e.g., a human subject) hypersialylated intravenous immunoglobulin (IVIg), a protein comprising a sialylated IgG Fc region, or a protein comprising a modified IgG Fc region that mimics IgG Fc sialylation.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Disclosed herein are compounds that can degrade lymphoid-specific helicase (HELLS) protein. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of proliferative diseases such as cancers.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 35/00 - Antineoplastic agents

Abstract

In some implementations, there is provided a process for personalized learning. In some aspects, there is provided receiving, by a user equipment, a configuration for a machine learning model, the configuration comprising a plurality of weights determined by a server during a first phase training of the machine learning model; initiating, by the user equipment, a second phase of training of the machine learning model using local training data at the user equipment to personalize the machine learning model without updating the plurality of weights of the machine learning model, and triggering, by the user equipment, a third phase of training of the machine learning model using at least the local training data at the user equipment to update the plurality of weights of the machine learning model and to further personalize the machine learning model to the user of the user equipment.

IPC Classes  ?

• G06N 3/08 - Learning methods

Abstract

Methods are provided for treatment of brain cancers with repeated administration of CART cells on a schedule that reflects the patient's inflammatory response to the introduced cells.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The present disclosure provides compositions and methods related to chimeric antigen receptors (CARs). In particular, the present disclosure provides CAR-based immunotherapeutic compositions that target tumor cells expressing GM2 for the treatment and prevention of cancer.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/42 - Cancer antigens

Abstract

The invention provides polycaprolactone and collagen substance compositions, as well as methods of making and using them.

IPC Classes  ?

• A61L 27/14 - Macromolecular materials
• A61L 27/24 - Collagen
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

The present embodiments relate generally to therapeutic techniques and more particularly to effective treatment of neurological disorders using noninvasive methods and apparatuses. Some embodiments relate to more effective vibrotactile stimulation, i.e., stronger physiological effects with less vibration power/amplitude, by means of a vibrotactile mechanical stimulator (tactor).

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/04 - Electrodes

Abstract

Described herein are localization polypeptides, RNA carrier polypeptides, polynucleotides, dimerization handles, cells, compositions, methods, and kits relating to the spatial localization of RNA in relation to a cell. In certain aspects, localization polypeptides and RNA carrier polypeptides may interact to carry an RNA of interest to a subcellular location or other location associated with a cellular membrane. In embodiments, such interaction may be covalent, for example, by the way of translational fusion, or may be inducible through a dimerization handle as described herein. In embodiments, RNA localization can be carried out on (and cells of the present disclosure can be) asymmetric cells, for example, neurons or neural progenitors. In embodiments, the ABI/PYL system can be utilized in conjunction with a catalytically-dead (i.e., nuclease-inactivated) RNA-guided CAS enzyme to precisely spatially localize an RNA of interest to a subcellular location of interest.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/22 - Ribonucleases
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present disclosure provides compositions and methods for identifying and treating cancer. In particular, the disclosure provides methods of identifying and treating cancer having decreased sensitivity or resistance to ganglioside GD2 directed therapies.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

Provided herein are methods for monitoring, identifying, assessing, circulating tumor DNA (ctDNA) for treating a subject or monitoring a subject having cancer, and related methods and uses thereof. In some embodiments, the disease or condition is a B cell lymphoma (BCL) relapsed or refractory.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6855 - Ligating adaptors
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignmentHomology search
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The disclosure relates to macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the macrocyclic compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/33 - Heterocyclic compounds